1. Scrip
  2. >>Business

Sun Eyes Big Stage For Concert’s Alopecia Asset

 
• By Anju Ghangurde

Sun outlines contours of path ahead for deuruxolitinib, which came to it via the recent $576m Concert deal and pits it against Eli Lilly's Olumiant and Pfizer's investigational candidate ritlecitinib. The Indian firm is believed to have had the JAK 1/2 inhibitor on its radar since August last year.

Sun Plans To Take Concert Alopecia Drug Global • Source: Shutterstock

The proposed $576m Concert Pharmaceuticals, Inc. deal and compliance issues at an Indian site dominated Sun Pharmaceutical Industries Ltd.’s fiscal third quarter earnings discussion, with the senior management providing some broad indications on which way things are headed.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip